Conflicting Impact of Alloreactive NK Cells on Transplantation Outcomes after Haploidentical Transplantation: Do the Reconstitution Kinetics of Natural Killer Cells Create These Differences?

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 10, 2011, Pages 1436-1442

  Zhao, Xiang Yu ^a   Chang, Ying Jun ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

Author keywords

GVHD; Haploidentical; HSCT; NK

Indexed keywords

ALLOIMMUNITY; CELL INTERACTION; CELL KINETICS; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HAPLOIDY; HUMAN; INFLAMMATION; INNATE IMMUNITY; NATURAL KILLER CELL; PERIPHERAL BLOOD STEM CELL; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; HISTOCOMPATIBILITY TESTING; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, INNATE; KILLER CELLS, NATURAL; LEUKEMIA; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 80052970005     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.05.020     Document Type: Review

References (49)

1. Fuchs E.J., Huang X.J., Miller J.S. HLA-haploidentical stem cell transplantation for hematologic malignancies. Biol Blood Marrow Transplant 2010, 16:S57-S63.
2. Ruggeri L., Mancusi A., Burchielli E., et al. Natural killer cell recognition of missing self and haploidentical hematopoietic transplantation. Semin Cancer Biol 2006, 16:404-411.
3. Locatelli F., Pende D., Maccario R., Mingari M.C., Moretta A., Moretta L. Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: how NK cells make the difference. Clin Immunol 2009, 133:171-178.
4. Ruggeri L., Capanni M., Casucci M., et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999, 94:333-339.
5. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W., Tosti Aea Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
6. Ruggeri L., Mancusi A., Capanni M., et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007, 110:433-440.
7. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
8. Passweg J.R., Tichelli A., Meyer-Monard S., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.
9. Rubnitz J.E., Inaba H., Ribeiro R.C., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010, 28:955-959.
10. Huang X.J., Liu D.H., Liu K.Y., et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion for the treatment of hematological malignancies. Bone Marrow Transplant 2006, 38:291-297.
11. Lu D.-P., Dong L., Wu T., et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006, 107:3065-3073.
12. Chang Y.J., Zhao X.Y., Huang X.J. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008, 14:323-334.
13. Huang X.J., Zhao X.Y., Liu D.H., Liu K.Y., Xu L.P. Deleterious effects of KIR ligand incompatibility on clinical outcomes in haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007, 21:848-851.
14. Zhao X.Y., Chang Y.J., Xu L.P., Liu D.H., Liu K.Y., Huang X.J. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors. Bone Marrow Transplant 2009, 44:721-728.
15. Zhao X.Y., Huang X.J., Liu K.Y., Xu L.P., Liu D.H. Reconstitution of natural killer cell receptor repertoires after unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation: analyses of CD94:NKG2A and killer immunoglobulin-like receptor expression and their associations with clinical outcome. Biol Blood Marrow Transplant 2007, 13:734-744.
16. Zhao X.Y., Huang X.J., Liu K.Y., Xu L.P., Liu D.H. Prognosis after unmanipulated HLA-haploidentical blood and marrow transplantation is correlated to the numbers of KIR ligands in recipients. Eur J Haematol 2007, 78:338-346.
17. Koenecke C., Shaffer J., Alexander S.I., et al. NK cell recovery, chimerism, function, and recognition in recipients of haploidentical hematopoietic cell transplantation following nonmyeloablative conditioning using a humanized anti-CD2 mAb, Medi-507. Exp Hematol 2003, 31:911-923.
18. Nguyen S., Dhedin N., Vernant J.P., et al. NK-cell reconstitution after haploidentical hematopoietic stem-cell transplantations: immaturity of NK cells and inhibitory effect of NKG2A override GvL effect. Blood 2005, 105:4135-4142.
19. Nguyen S., Kuentz M., Vernant J.P., et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008, 22:344-352.
20. Pfeiffer M.M., Feuchtinger T., Teltschik H.M., et al. Reconstitution of NK cell receptors influences NK activity and relapse rate after haploidentical transplantation of T and B cell depleted grafts in children. Haematologica 2010, 95:1381-1388.
21. Schulze A., Schirutschke H., Oelschlagel U., et al. Altered phenotype of natural killer cell subsets after haploidentical stem cell transplantation. Exp Hematol 2008, 36:378-389.
22. Stern M., de Angelis C., Urbani E., et al. Natural killer-cell KIR repertoire reconstitution after haploidentical SCT. Bone Marrow Transplant 2010, 45:1607-1610.
23. Vago L., Forno B., Sormani M.P., et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008, 112:3488-3499.
24. Pende D., Marcenaro S., Falco M., et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009, 113:3119-3129.
25. Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008, 20:581-587.
26. Leung W.L.R., Turner V., Lang P., et al. Determinants of antileukemia effects of allogeneic NK cells. J Immunol 2004, 172:644-650.
27. Leung W.L.R., Triplett B., Turner V., et al. Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors. J Immunol 2005, 174:6540-6545.
28. Gagne K., Brizard G., Gueglio B., et al. Relevance of KIR gene polymorphisms in bone marrow transplantation outcome. Hum Immunol 2002, 63:271-280.
29. Bishara A., De Santis D., Witt C.C., et al. The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD. Tissue Antigens 2004, 63:204-211.
30. Symons H.J., Leffell M.S., Rossiter N.D., Zahurak M., Jones R.J., Fuchs E.J. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010, 16:533-542.
31. Chen X., Hale G.A., Barfield R., et al. Rapid immune reconstitution after a reduced-intensity conditioning regimen and a CD3-depleted haploidentical stem cell graft for paediatric refractory haematological malignancies. Br J Haematol 2006, 135:524-532.
32. Moretta A., Pende D., Locatelli F., Moretta L. Activating and inhibitory killer immunoglobulin-like receptors (KIR) in haploidentical haemopoietic stem cell transplantation to cure high-risk leukaemias. Clin Exp Immunol 2009, 157:325-331.
33. Nguyen S., Beziat V., Dhedin N., et al. HLA-E upregulation on IFN-gamma-activated AML blasts impairs CD94/NKG2A-dependent NK cytolysis after haplo-mismatched hematopoietic SCT. Bone Marrow Transplant 2009, 43:693-699.
34. Orr M.T., Lanier L.L. Natural killer cell education and tolerance. Cell 2010, 142:847-856.
35. Brodin P., Lakshmikanth T., Johansson S., Kärre K., Höglund P. The strength of inhibitory input during education quantitatively tunes the functional responsiveness of individual natural killer cells. Blood 2009, 113:2434-2441.
36. Fauriat C., Ivarsson M.A., Ljunggren H.-G., Malmberg K.-J., Michaëlsson J. Education of human natural killer cells by activating killer cell immunoglobulin-like receptors. Blood 2010, 115:1166-1174.
37. Haas P., Loiseau P., Tamouza R., et al. NK-cell education is shaped by donor HLA genotype after unrelated allogeneic hematopoietic stem cell transplantation. Blood 2011, 117:1021-1029.
38. Schönberg K., Sribar M., Enczmann J., Fischer J.C., Uhrberg M. Analyses of HLA-C-specific KIR repertoires in donors with group A and B haplotypes suggest a ligand-instructed model of NK cell receptor acquisition. Blood 2011, 117:98-107.
39. Yawata M., Yawata N., Draghi M., Partheniou F., Little A.-M., Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response. Blood 2008, 112:2369-2380.
40. Yu J., Venstrom J.M., Liu X.-R., et al. Breaking tolerance to self, circulating natural killer cells expressing inhibitory KIR for non-self HLA exhibit effector function after T cell-depleted allogeneic hematopoietic cell transplantation. Blood 2009, 113:3875-3884.
41. Brodin P., Hoglund P. Beyond licensing and disarming: a quantitative view on NK-cell education. Eur J Immunol 2008, 38:2934-2937.
42. Elliott J.M., Wahle J.A., Yokoyama W.M. MHC class I-deficient natural killer cells acquire a licensed phenotype after transfer into an MHC class I-sufficient environment. J Exp Med 2010, 207:2073-2079.
43. Orr M.T., Murphy W.J., Lanier L.L. "Unlicensed" natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol 2010, 11:321-327.
44. Kim S., Sunwoo J.B., Yang L., et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc Natl Acad Sci U S A 2008, 105:3053-3058.
45. Björklund A.T., Schaffer M., Fauriat C., et al. NK cells expressing inhibitory KIR for non-self-ligands remain tolerant in HLA-matched sibling stem cell transplantation. Blood 2010, 115:2686-2694.
46. Cooley S., McCullar V., Wangen R., et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood 2005, 106:4370-4376.
47. Fehniger T.A., Cooper M.A., Nuovo G.J., et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003, 101:3052-3057.
48. Marcenaro E., Cantoni C., Pesce S., et al. Uptake of CCR7 and acquisition of migratory properties by human KIR+ NK cells interacting with monocyte-derived DC or EBV cell lines: regulation by KIR/HLA-class I interaction. Blood 2009, 114:4108-4116.
49. Cooper M.A., Fehniger T.A., Turner S.C., et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56bright subset. Blood 2001, 97:3146-3151.